Your browser doesn't support javascript.
loading
Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?"
Krebs-Brown, Axel; Munafo, Alain; Gaikwad, Sumedh; Urgatz, Bogumila; Castello-Bridoux, Claire.
Affiliation
  • Krebs-Brown A; Merck KGaA, Darmstadt, Germany.
  • Munafo A; Merck Institute for Pharmacometrics (An Affiliate of Merck KGaA, Darmstadt, Germany), Lausanne, Switzerland.
  • Gaikwad S; Merck KGaA, Darmstadt, Germany.
  • Urgatz B; Merck KGaA, Darmstadt, Germany.
  • Castello-Bridoux C; Direction des Affaires Médicales, Merck Santé s.a.s, 37 rue Saint-Romain, 69008, Lyon, France. claire.castello-bridoux@merckgroup.com.
Clin Pharmacokinet ; 59(2): 265-267, 2020 02.
Article in En | MEDLINE | ID: mdl-31802400
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thyroxine Type of study: Prognostic_studies Limits: Humans Language: En Journal: Clin Pharmacokinet Year: 2020 Document type: Article Affiliation country: Germany Country of publication: Switzerland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thyroxine Type of study: Prognostic_studies Limits: Humans Language: En Journal: Clin Pharmacokinet Year: 2020 Document type: Article Affiliation country: Germany Country of publication: Switzerland